In this issue:
Adjuvant melatonin for preventing recurrence and mortality after lung cancer resection
Baseline medications and outcomes of first-line pembrolizumab vs. chemotherapy for NSCLC
Tremelimumab + durvalumab retreatment and 4-year outcomes in mesothelioma
Maintenance nivolumab and ipilimumab in extensive-disease SCLC
Blood-based TMB assessment in first-line treatment of metastatic NSCLC
Lorlatinib intra/extracranial efficacy in ALK-positive NSCLC after second-generation ALK TKIs
Second-line nivolumab in relapsed SCLC
Prophylactic cranial irradiation ±hippocampus avoidance in SCLC
ICI benefit better with lower tumour volume in advanced NSCLC
Anatomical segmentectomy vs. pulmonary lobectomy for stage I NSCLC
Please login below to download this issue (PDF)